VivoSeq
Other

Intracanal Medicament

0

Pipeline Programs

3

Active Trials

0

Companies Involved

Intracanal Medicament is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

11

clinical trials

Completed4 · 36%
Unknown status4 · 36%
Not yet recruiting2 · 18%
Recruiting1 · 9%

Trial Activity

11 trials

The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament
Recruiting··Phase 2/3·NCT06207253·48 enrolled
Tobradex as Intracanal Medicament
Completed·UUmm Al-Qura University·N/A·NCT07332936·43 enrolled
Effect of Nitrofurantion Used as an Intracanal Medicament
Unknown status··Phase 1·NCT05074628·38 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)